Film production company of son of Welsh tech billionaire Sir Terry Matthews in running for Oscar success

Film production company Brookstreet Pictures, set up by Trevor Matthews the son of Welsh tech billionaire Sir Terry Matthews, is being tipped for Oscar success for its co-produced film The Brutalist. Th cinematic historical drama explores themes of ambition, identity and the ‘American dream’ in the journey of an Hungarian architect who emigrates to post-war…

World premiere of the Until Dawn movie trailer

This year marks the 10th anniversary of the release of the Until Dawn game, and I’m thrilled to share with you the world premiere of the trailer for Until Dawn the movie, coming to theaters.

Play Video

PlayStation Productions and Sony Pictures have been working closely with director/producer David F. Sandberg (Annabelle: Creation, Lights Out) and writer/producer Gary Dauberman (It, Annabelle series, The Nun series) to translate Until Dawn to the big screen. In making that transition, we wanted to honor the spirit of the Until Dawn game – especially the idea of decisions with branching paths and deadly consequences – while adapting it in a way that maximizes both the entertainment and terror for moviegoers.

Though the movie’s story is set in the same world as the game, it was important to us that the movie wasn’t just a retelling. Instead, the film will feature fresh characters in a new, original story. If you’ve played the game, you know not everything is what it seems. With the movie we wanted to keep the audience guessing until the end. We can’t wait for fans to discover how the events of the movie connect to the Until Dawn game.

Peter Stormare, whom you know as Dr. Hill in the game, is one of those key connecting links. The film will delve into his character’s involvement in the events of the game, raising questions for fans to explore. Given Peter’s role spanning both projects, it’s only fitting he introduce the first Until Dawn movie trailer to the world:

“I have been lucky to be part of Until Dawn since the original, incredible, super terrifying game, and that’s why I’m so excited to be part of this film, because the whole thing is a love letter to horror, and it completely honors the spirit of the game. The movie is going to be full of fresh characters and victims in a brand-new story, loaded with twists. So whether you’re a longtime fan or you’re discovering it for the first time, get ready for Until Dawn like you’ve never seen it before.”
– Peter Stormare

Now, enjoy the world premiere of the trailer, and keep checking back, as there will be plenty more updates between now and when Until Dawn hits theaters later this year.

Malaysia’s Medical Tourism Brand Gets Power Boost as IJN Clinches ASEAN Cardiology Spotlight

By The MalketeerBrand Malaysia’s Healthcare Equity Surges with Regional RecognitionIn a significant boost to Malaysia’s medical tourism brand equity, the Institut Jantung Negara (IJN) has secured a prestigious position as a live transmission site for ASEAN’s premier cardiology event, the A-Z Vietnam Interventional Meeting which takes takes place from  January 15-17, 2025.This strategic win positions Malaysia’s healthcare brand alongside regional powerhouses in the competitive medical tourism landscape.Reputation Marketing Through Medical ExcellenceThe selection of IJN’s Paediatric & Congenital Heart Centre (PCHC) showcases how clinical excellence can be leveraged as a powerful marketing tool.By broadcasting live procedures performed on patients ranging from three-week-old infants to teenagers, IJN is effectively demonstrating its brand promise of cutting-edge medical expertise to a highly influential ASEAN audience.Building Brand Authority Through Knowledge LeadershipDr. Marhisham Che Mood, Head of PCHC, highlighted how this platform strengthens IJN’s thought leadership position: “This recognition amplifies our brand presence across ASEAN while establishing our medical professionals as authoritative voices in pediatric cardiology.”Leveraging Events for Destination MarketingThe timing couldn’t be more strategic for Malaysia’s medical tourism aspirations.As one of four finalists in the Flagship Medical Tourism Hospital (FMTH) programme, IJN’s participation in this high-profile event serves as a compelling case study in how healthcare institutions can utilise professional platforms to enhance medical destination marketing efforts.ROI Beyond Traditional Marketing MetricsChief Clinical Officer Datuk Dr. Shaiful Azmi Yahya’s perspective highlights the long-term brand building potential: “This isn’t just about immediate visibility. It’s about positioning Malaysia as the go-to destination for advanced cardiac care in the region.”Building Trust Through Live DemonstrationThe live transmission format serves as an innovative trust-building mechanism, allowing IJN to showcase its capabilities in real-time to a specialised audience.This transparency in demonstrating complex procedures like Transcatheter Pulmonary Valve Implantation and Ductal Stenting acts as a powerful testimonial to the institution’s expertise.For marketers in the healthcare sector, IJN’s strategic leverage of this event offers valuable lessons in:Building credibility through peer recognitionUsing specialised events as brand-building platformsConverting technical excellence into marketing advantageStrengthening country-of-origin branding in healthcareAs the medical tourism sector becomes increasingly competitive, IJN’s participation in the A-Z Vietnam Interventional Meeting demonstrates how healthcare institutions can transform clinical excellence into compelling brand narratives that resonate across borders.MARKETING Magazine is not responsible for the content of external sites.

Malaysia’s Medical Tourism Brand Gets Power Boost as IJN Clinches ASEAN Cardiology Spotlight

By The MalketeerBrand Malaysia’s Healthcare Equity Surges with Regional RecognitionIn a significant boost to Malaysia’s medical tourism brand equity, the Institut Jantung Negara (IJN) has secured a prestigious position as a live transmission site for ASEAN’s premier cardiology event, the A-Z Vietnam Interventional Meeting which takes takes place from  January 15-17, 2025.This strategic win positions Malaysia’s healthcare brand alongside regional powerhouses in the competitive medical tourism landscape.Reputation Marketing Through Medical ExcellenceThe selection of IJN’s Paediatric & Congenital Heart Centre (PCHC) showcases how clinical excellence can be leveraged as a powerful marketing tool.By broadcasting live procedures performed on patients ranging from three-week-old infants to teenagers, IJN is effectively demonstrating its brand promise of cutting-edge medical expertise to a highly influential ASEAN audience.Building Brand Authority Through Knowledge LeadershipDr. Marhisham Che Mood, Head of PCHC, highlighted how this platform strengthens IJN’s thought leadership position: “This recognition amplifies our brand presence across ASEAN while establishing our medical professionals as authoritative voices in pediatric cardiology.”Leveraging Events for Destination MarketingThe timing couldn’t be more strategic for Malaysia’s medical tourism aspirations.As one of four finalists in the Flagship Medical Tourism Hospital (FMTH) programme, IJN’s participation in this high-profile event serves as a compelling case study in how healthcare institutions can utilise professional platforms to enhance medical destination marketing efforts.ROI Beyond Traditional Marketing MetricsChief Clinical Officer Datuk Dr. Shaiful Azmi Yahya’s perspective highlights the long-term brand building potential: “This isn’t just about immediate visibility. It’s about positioning Malaysia as the go-to destination for advanced cardiac care in the region.”Building Trust Through Live DemonstrationThe live transmission format serves as an innovative trust-building mechanism, allowing IJN to showcase its capabilities in real-time to a specialised audience.This transparency in demonstrating complex procedures like Transcatheter Pulmonary Valve Implantation and Ductal Stenting acts as a powerful testimonial to the institution’s expertise.For marketers in the healthcare sector, IJN’s strategic leverage of this event offers valuable lessons in:Building credibility through peer recognitionUsing specialised events as brand-building platformsConverting technical excellence into marketing advantageStrengthening country-of-origin branding in healthcareAs the medical tourism sector becomes increasingly competitive, IJN’s participation in the A-Z Vietnam Interventional Meeting demonstrates how healthcare institutions can transform clinical excellence into compelling brand narratives that resonate across borders.MARKETING Magazine is not responsible for the content of external sites.

15 book-to-movie adaptations to get (very) excited about in 2025

As 2025 gets into gear, perhaps the best way to fulfill that new year resolution about reading more might be going to the movies. There is a raft of book-to-film adaptations that are heading to multiplexes this year. From literary classics to book club bestsellers via dynamic graphic novels, there is a dizzying array of genres and style to explore, pitching some of literature’s greatest authors (Mary Shelley, Stephen King) with some of cinema’s most respected auteurs (Guillermo del Toro, Chloé Zhao, Edgar Wright). Below is our pick of the most mouthwatering page to screen crossovers – it’s time to curl up with a great film.
Photograph: Time Out

1. The Ballad of a Small Player
Fresh from the Vatican shenanigans of Conclave, director Edward Berger travels to China for another literary adaptation: this time of Lawrence Osborne’s 2014 book. The travel journalist-turned-novelist’s crime tale The Forgiven was adapted in 2021, with Ralph Fiennes and Jessica Chastain as a married couple all at sea in Morocco, and The Ballad of a Small Player has invited further Graham Greene comparisons (think gone-to-seed Brits abroad). Colin Farrell plays a high-stakes gambler who passes himself off as an English lord while lying low in the casinos of Macau. Throw in Tilda Swinton and we’re sold. 

Photograph: Time Out

2. Bridget Jones: Mad About the Boy
Whether you are a singleton or smug married, who cannot rejoice at the return of everyone’s favourite everywoman? Nine years after Bridget Jones’ Baby, Renée Zellweger is back as Bridget, this time juggling single motherhood (Colin Firth’s Mark Darcy has passed away) as well as men new and familiar; toy boy Roxster (One Day’s Leo Woodall), Chiwetel Ejiofor’s teacher and the love rat’s love rat, Daniel Cleaver (Hugh Grant). Taking its cues from Helen Fielding’s novel, get ready for an older though not necessarily wiser Bridget. 

Photograph: Time Out

3. Die, My Love
The surprising, if enticing-sounding duo of Lynne Ramsay (director) and Jennifer Lawrence (producer/star) have teamed up to adapt Ariana Harwicz’s decidedly Lynchian 2017 novel. Lawrence plays a woman beset by psychological traumas, with Robert Pattinson as her husband and LaKeith Stanfield as her lover. Ramsay has always taken liberties with her source materials (see We Need To Talk About Kevin and You Were Never Really Here), so prepare for the unexpected.

Photograph: Time Out

4. The Electric State
Made by the Marvel brain trust of directors Joe and Anthony Russo and screenwriters Christopher Markus and Stephen McFeely, this sci-fi adventure posits an alternative 1984 (A.I. is now dominant, obvs) in which a teen orphan (Millie Bobby Brown) joins forces with a robot and a drifter (Chris Pratt) to find her missing brother. Reworked from Simon Stålenhag’s 2018 graphic novel, this is giving off big ’80s Amblin energy. 

Photograph: Time Out

5. Frankenstein 
Guillermo del Toro is the Godfather of the Gothic and his adaptation of Mary Shelley’s 1818 novel is the dictionary definition of labour of love. Promising to cleave closer to Shelley’s vision than previous versions, it stars Oscar Isaac as Victor Frankenstein and the normally easy-on-the-eye Jacob Elordi as the monster alongside Mia Goth and Christoph Waltz. This one will make Nosferatu look like Hundreds of Beavers. Probably.

Photograph: Time Out

6. Hamnet
After a foray into the MCU with Eternals, Nomadland’s Chloé Zhao explores literary history, focusing on William Shakespeare (Paul Mescal) and Anne Hathaway (Jessie Buckley) coping with the death of their 11-year-old son Hamnet (Jacobi Jupe, brother of A Quiet Place’s Noah). Based on Maggie O’Farrell’s soulful 2020 novel, it also stars Joe Alwyn and Emily Watson. Expect tears and awards in equal measures.

Photograph: Time Out

7. Highest 2 Lowest
Spike Lee’s next joint is a reinterpretation of Akira Kurosawa’s 1963 procedural High and Low, itself a loose adaptation of Evan Hunter’s 1959 novel King’s Ransom. In his fifth mouth-watering collaboration with Lee, Denzel Washington is a high-flying music mogul but the lead according to Lee is rapper A$AP Rocky. Also featuring Ice Spice, Ilfenesh Hadera and Jeffrey Wright, kidnapping, extortion and a tonne of cinematic style. 

Photograph: Time Out

8. The History of Sound
A dream team of Paul Mescal and Josh O’Connor comes together in an adaptation of American novelist Ben Shattuck’s award-winning 2018 short story. It’s a love story set during War World I and its immediate aftermath about two young men, Lionel (Mescal) and David (O’Connor), who set out to record the lives, voices and music of their American countryman. Directed by Olivier Hermanus (Moffie, Living), it promises a balance of intimate moments combined with an epic sweep across 20th century America. 

Photograph: Time Out

9. Hot Milk
Set under the scorching Spanish sun, British filmmaker Rebecca Lenkiewicz’s take on Deborah Levy’s bestseller sees a mother, Rose (Fiona Shaw), and her daughter, Sofia (Sex Education’s Emma Mackey), travel to Almeria looking for a cure for Rose’s paralysis. Once there, Sofia falls under the spell of enigmatic seamstress Ingrid (Phantom Thread’s Vicky Krieps). The screenwriter of ida, She Said and Small Axe, Lenkiewicz’s trademark is knotty complexity that she will surely bring to bare on uneasy parent-child dynamics.

Photograph: Time Out

10. The Housemaid
Based on the first in a series of books by American thriller author Freida McFadden, The Housemaid is a full-on thriller that redefines twisty-turny. The fast-rising Sydney Sweeney plays Millie, a young woman who takes a job as a housekeeper for the Winchesters (Amanda Seyfried is matriarch Nina), a well-to-do couple harbouring dark secrets. Directed by Paul Feig, working in the similar vein to A Simple Favor, this could be 2025’s Gone Girl.

Photograph: Time Out

11. The Man In My Basement
Sourced from Walter Mosley’s 2004 novel, London-based filmmaker Nadia Latif’s debut feature pitches Corey Hawkins’ down-on-his-luck Black man about to lose his ancestral home, against Willem Dafoe’s mysterious businessman who offers to clear his debts by renting his basement. The premise suggests a thought-provoking thriller operating at the intersection of race and murky morality.

Photograph: Time Out

12. Mickey 17
Bong Joon Ho’s long awaited follow up to Parasite uses Edward Ashton’s 2022 science fiction novel Mickey7, as a jumping off point. Robert Pattinson plays the title character who signs up to the so-called ‘expendable’ programme, with a mission to achieve: to colonise a remote ice planet. The twist is he can die every day and be replaced by a replica of himself. 

Photograph: Time Out

13. No Other Choice
Previously adapted by Costa-Gavras in 2005, Donald Westlake’s thriller The Ax now gets the Park Chan-wook treatment. A South Korean man (Squid Game’s Lee Byung-hun) is fired from his job after 25 years and becomes so desperate he resorts to killing his competitors in the job market. Nifty premise, social satire, director Park’s visuals? Unmissable. 

Photograph: Time Out

14. The Running Man
Edgar Wright is tackling the 1982 Stephen King dystopian thriller about a TV show that sees contestants chased by murderous killers to win money. Glen Powell plays the hero who bucks the system, joined by Josh Brolin as the show’s producer and Colman Domingo as its flamboyant host.  Wright has promised his film will cleave closer to King than the 1987 Arnold Schwarzenegger vehicle so don’t expect those classic kiss-off lines. What a pain in the neck. 

Photograph: Time Out

15. The Thursday Murder Club
The first in Richard Osman’s OAPs-crack-crimes series comes to the big screen courtesy of Harry Potter director Chris Columbus. TTMC follows four amateur sleuths (Helen Mirren, Sir Ben Kingsley, Pierce Brosnan and Celia Imrie) who solve cold cases for fun in a retirement home, only to be pulled into a real-life mystery involving the death of a local property developer. There’ll be heart, humour, homicides and, if it follows the book, lots of nods to modern British life.These are the must-see films for 2025 you can’t miss.The 22 best TV and streaming shows to stream this year.

15 book-to-movie adaptations to get (very) excited about in 2025

As 2025 gets into gear, perhaps the best way to fulfill that new year resolution about reading more might be going to the movies. There is a raft of book-to-film adaptations that are heading to multiplexes this year. From literary classics to book club bestsellers via dynamic graphic novels, there is a dizzying array of genres and style to explore, pitching some of literature’s greatest authors (Mary Shelley, Stephen King) with some of cinema’s most respected auteurs (Guillermo del Toro, Chloé Zhao, Edgar Wright). Below is our pick of the most mouthwatering page to screen crossovers – it’s time to curl up with a great film.
Photograph: Time Out

1. The Ballad of a Small Player
Fresh from the Vatican shenanigans of Conclave, director Edward Berger travels to China for another literary adaptation: this time of Lawrence Osborne’s 2014 book. The travel journalist-turned-novelist’s crime tale The Forgiven was adapted in 2021, with Ralph Fiennes and Jessica Chastain as a married couple all at sea in Morocco, and The Ballad of a Small Player has invited further Graham Greene comparisons (think gone-to-seed Brits abroad). Colin Farrell plays a high-stakes gambler who passes himself off as an English lord while lying low in the casinos of Macau. Throw in Tilda Swinton and we’re sold. 

Photograph: Time Out

2. Bridget Jones: Mad About the Boy
Whether you are a singleton or smug married, who cannot rejoice at the return of everyone’s favourite everywoman? Nine years after Bridget Jones’ Baby, Renée Zellweger is back as Bridget, this time juggling single motherhood (Colin Firth’s Mark Darcy has passed away) as well as men new and familiar; toy boy Roxster (One Day’s Leo Woodall), Chiwetel Ejiofor’s teacher and the love rat’s love rat, Daniel Cleaver (Hugh Grant). Taking its cues from Helen Fielding’s novel, get ready for an older though not necessarily wiser Bridget. 

Photograph: Time Out

3. Die, My Love
The surprising, if enticing-sounding duo of Lynne Ramsay (director) and Jennifer Lawrence (producer/star) have teamed up to adapt Ariana Harwicz’s decidedly Lynchian 2017 novel. Lawrence plays a woman beset by psychological traumas, with Robert Pattinson as her husband and LaKeith Stanfield as her lover. Ramsay has always taken liberties with her source materials (see We Need To Talk About Kevin and You Were Never Really Here), so prepare for the unexpected.

Photograph: Time Out

4. The Electric State
Made by the Marvel brain trust of directors Joe and Anthony Russo and screenwriters Christopher Markus and Stephen McFeely, this sci-fi adventure posits an alternative 1984 (A.I. is now dominant, obvs) in which a teen orphan (Millie Bobby Brown) joins forces with a robot and a drifter (Chris Pratt) to find her missing brother. Reworked from Simon Stålenhag’s 2018 graphic novel, this is giving off big ’80s Amblin energy. 

Photograph: Time Out

5. Frankenstein 
Guillermo del Toro is the Godfather of the Gothic and his adaptation of Mary Shelley’s 1818 novel is the dictionary definition of labour of love. Promising to cleave closer to Shelley’s vision than previous versions, it stars Oscar Isaac as Victor Frankenstein and the normally easy-on-the-eye Jacob Elordi as the monster alongside Mia Goth and Christoph Waltz. This one will make Nosferatu look like Hundreds of Beavers. Probably.

Photograph: Time Out

6. Hamnet
After a foray into the MCU with Eternals, Nomadland’s Chloé Zhao explores literary history, focusing on William Shakespeare (Paul Mescal) and Anne Hathaway (Jessie Buckley) coping with the death of their 11-year-old son Hamnet (Jacobi Jupe, brother of A Quiet Place’s Noah). Based on Maggie O’Farrell’s soulful 2020 novel, it also stars Joe Alwyn and Emily Watson. Expect tears and awards in equal measures.

Photograph: Time Out

7. Highest 2 Lowest
Spike Lee’s next joint is a reinterpretation of Akira Kurosawa’s 1963 procedural High and Low, itself a loose adaptation of Evan Hunter’s 1959 novel King’s Ransom. In his fifth mouth-watering collaboration with Lee, Denzel Washington is a high-flying music mogul but the lead according to Lee is rapper A$AP Rocky. Also featuring Ice Spice, Ilfenesh Hadera and Jeffrey Wright, kidnapping, extortion and a tonne of cinematic style. 

Photograph: Time Out

8. The History of Sound
A dream team of Paul Mescal and Josh O’Connor comes together in an adaptation of American novelist Ben Shattuck’s award-winning 2018 short story. It’s a love story set during War World I and its immediate aftermath about two young men, Lionel (Mescal) and David (O’Connor), who set out to record the lives, voices and music of their American countryman. Directed by Olivier Hermanus (Moffie, Living), it promises a balance of intimate moments combined with an epic sweep across 20th century America. 

Photograph: Time Out

9. Hot Milk
Set under the scorching Spanish sun, British filmmaker Rebecca Lenkiewicz’s take on Deborah Levy’s bestseller sees a mother, Rose (Fiona Shaw), and her daughter, Sofia (Sex Education’s Emma Mackey), travel to Almeria looking for a cure for Rose’s paralysis. Once there, Sofia falls under the spell of enigmatic seamstress Ingrid (Phantom Thread’s Vicky Krieps). The screenwriter of ida, She Said and Small Axe, Lenkiewicz’s trademark is knotty complexity that she will surely bring to bare on uneasy parent-child dynamics.

Photograph: Time Out

10. The Housemaid
Based on the first in a series of books by American thriller author Freida McFadden, The Housemaid is a full-on thriller that redefines twisty-turny. The fast-rising Sydney Sweeney plays Millie, a young woman who takes a job as a housekeeper for the Winchesters (Amanda Seyfried is matriarch Nina), a well-to-do couple harbouring dark secrets. Directed by Paul Feig, working in the similar vein to A Simple Favor, this could be 2025’s Gone Girl.

Photograph: Time Out

11. The Man In My Basement
Sourced from Walter Mosley’s 2004 novel, London-based filmmaker Nadia Latif’s debut feature pitches Corey Hawkins’ down-on-his-luck Black man about to lose his ancestral home, against Willem Dafoe’s mysterious businessman who offers to clear his debts by renting his basement. The premise suggests a thought-provoking thriller operating at the intersection of race and murky morality.

Photograph: Time Out

12. Mickey 17
Bong Joon Ho’s long awaited follow up to Parasite uses Edward Ashton’s 2022 science fiction novel Mickey7, as a jumping off point. Robert Pattinson plays the title character who signs up to the so-called ‘expendable’ programme, with a mission to achieve: to colonise a remote ice planet. The twist is he can die every day and be replaced by a replica of himself. 

Photograph: Time Out

13. No Other Choice
Previously adapted by Costa-Gavras in 2005, Donald Westlake’s thriller The Ax now gets the Park Chan-wook treatment. A South Korean man (Squid Game’s Lee Byung-hun) is fired from his job after 25 years and becomes so desperate he resorts to killing his competitors in the job market. Nifty premise, social satire, director Park’s visuals? Unmissable. 

Photograph: Time Out

14. The Running Man
Edgar Wright is tackling the 1982 Stephen King dystopian thriller about a TV show that sees contestants chased by murderous killers to win money. Glen Powell plays the hero who bucks the system, joined by Josh Brolin as the show’s producer and Colman Domingo as its flamboyant host.  Wright has promised his film will cleave closer to King than the 1987 Arnold Schwarzenegger vehicle so don’t expect those classic kiss-off lines. What a pain in the neck. 

Photograph: Time Out

15. The Thursday Murder Club
The first in Richard Osman’s OAPs-crack-crimes series comes to the big screen courtesy of Harry Potter director Chris Columbus. TTMC follows four amateur sleuths (Helen Mirren, Sir Ben Kingsley, Pierce Brosnan and Celia Imrie) who solve cold cases for fun in a retirement home, only to be pulled into a real-life mystery involving the death of a local property developer. There’ll be heart, humour, homicides and, if it follows the book, lots of nods to modern British life.These are the must-see films for 2025 you can’t miss.The 22 best TV and streaming shows to stream this year.

U.S. and China Just Set New Road Rules for Science Collaboration. Americans Will Benefit If We Don’t Scrap Joint Research

Amid heightened U.S.-China strategic and technology competition, bilateral scientific collaboration has become increasingly challenging. China’s broad military-civil fusion and espionage efforts have heightened Washington’s concerns that any collaboration could be exploited to advance Beijing’s military development. China’s increasingly closed information environment has also exacerbated doubts around whether the results and benefits of collaboration will be properly shared.
In this environment, the renewal on Dec. 13 of the two countries’ long-standing science and technology agreement (STA) was an important step toward stabilizing the bilateral scientific relationship. While a lapse of the STA might have had modest immediate impact, prominent scientists noted that canceling the agreement would have sent a damaging signal. The recently amended STA, with added guardrails in place to address national security and reciprocity concerns, provides space for continued beneficial scientific cooperation with the People’s Republic of China (PRC) while also resisting pressure for decoupling.
The U.S.-PRC Agreement on Cooperation in Science and Technology, signed in 1979, was the first major agreement between the two countries after the normalization of diplomatic relations. Since that STA’s signing more than four decades ago, the two governments have renewed it roughly every five years, most recently during the first Trump administration, which added a new section to the agreement in an effort to strengthen intellectual property rights protections.
The 2024 changes to the STA strengthen researcher protections, reciprocity on data-sharing, and accountability for continued government-to-government scientific cooperation. The amended agreement embodies the outgoing Biden administration’s “de-risking” of relations with China. The goal was to set clear guardrails around science and technology cooperation, especially in areas that could aid China’s military, while not seeking to decouple scientific progress that could damage not only the United States’ research and innovation, but also the lives of its citizens. The revised STA is a good reminder that, with the right controls in place, scientific cooperation with China can still provide important benefits.
The STA does not mandate any cooperation. Instead, it is an umbrella agreement that sets consistent terms and protections for U.S. science agencies that pursue cooperative arrangements with their Chinese counterparts, such as joint projects or memorandums of understanding.
Cooperation under the STA has benefited the U.S. in a number of areas, including advances in maternal nutrition, earthquake prediction, the collection of influenza data for vaccine development, more timely and accurate air quality data, and agricultural pest management practices that helped avert significant crop losses.
Just as importantly, continued scientific engagement provides visibility on scientific research in China—visibility that the United States might lose if research collaboration were to be cut off. China now conducts world-leading research in a range of scientific areas, which are important for the United States to stay up to date on for its own scientific advances.
The STA has also benefited China through specific projects in HIV/AIDS prevention, child health, flood control, and climate change monitoring, among other areas, and more broadly in establishing collaboration with leading U.S. institutions. China’s leadership, concerned about losing such linkages, made extending the agreement a priority. Speaking a few days after the renewal in December, a spokesperson from China’s Ministry of Foreign Affairs cited the STA renewal as “an important step in implementing the consensus reached during the China-U.S. presidential meeting” while Chinese state media touted benefits “for both nations and the world” in continued bilateral scientific research collaboration.
This is the first major rewrite since the STA was originally signed. The agreement has been updated to be more consistent with current issues as well as to account for the state of U.S.-China relations. Changes include provisions emphasizing the importance of researcher safety and well-being; a practical dispute resolution mechanism to address implementation concerns, which replaces an outdated high-level Joint Commission on Science and Technology; and multiple sections on transparency and data-sharing.
Before the negotiations started, the biggest concerns for U.S. and global researchers were data-sharing, transparency, and integrity. China has what is arguably the world’s strictest set of overlapping laws and regulations limiting cross-border data flows, which makes international collaboration increasingly fraught. For example, foreign researchers collaborating with Chinese counterparts can face difficulty exporting or accessing data from joint projects to anywhere outside of China.
If they do export data out of China, foreign and Chinese researchers alike could face challenges—including the risk of arrest—or other unpredictable enforcement of relevant data laws and regulations, which focus on controlling “important data,” a term that is used in China’s data laws, but insufficiently defined. China’s move in April 2023 to limit international access to its primary academic database (known as CNKI), particularly for scientific conference proceedings and dissertations, raised broader concerns on China’s commitment to open science.
A new section in the STA seeks to address these concerns with commitments around data management, access, and transparency. Skeptics may question whether strengthened provisions will truly address the long-standing data issues with China that have built up over several years. But Beijing, acting largely out of concerns that its data regime was damaging its business environment, took steps in the right direction at the same time as the agreement was being renegotiated; in March 2024, Chinese authorities announced important—if incomplete—progress on relaxing some of their onerous and self-damaging restrictions on sharing data.
The STA negotiation provided an opportunity for the United States to push on these adjustments to China’s data regime, including clarification around implementation and how these changes will be applied to scientific collaboration. The new dispute resolution mechanism can be used to provide more accountability, with provisions for U.S. researchers to cease cooperation if their Chinese counterparts do not reciprocate. Data-sharing issues are common in joint research with China, and this mechanism will not solve all these problems—but it’s welcome progress that should also benefit nongovernmental researchers.
The STA has been a source of controversy, particularly with some members of the U.S. Congress, including within the House select committee on the Chinese Communist Party, who argue that research shared under the agreement could support China’s military modernization.
These criticisms are misplaced. Officials across the U.S. executive branch and Congress—and from both parties—are clear-eyed about China’s broad-ranging efforts to leverage civilian, commercial, and academic research for military and defense purposes, and the threat that this poses to U.S. national security. This naturally circumscribes the scope for cooperation, and Washington has been clear that the STA does not support any cooperation on critical and emerging technologies.
Before any proposed cooperation under the STA is allowed to proceed, it is subject to an internal risk-benefit review, including on national security risks. The Biden administration strengthened this processto ensure any national security risks are sufficiently considered and addressed.
Members of Congress and national security experts have expressed additional concerns—unrelated to the STA, though sometimes conflated with it—around broader Chinese access to U.S. labs and universities. These are being addressed through separate research security efforts. In July, the White House Office of Science and Technology Policy published new “Guidelines for Research Security Programs” at U.S. institutes and universities that receive significant federal funding—highlighting national security risks from China and its exploitation of international scientific collaboration while preserving the United States’ openness.
But there is clearly more work to do in protecting U.S. labs. Universities have made progress in their own research security efforts, however, and the National Science Foundation announced new funding in July to establish a national center and five regional centers to share risks, training, and best practices across higher education.
The amended U.S.-PRC STA can serve as a useful reference and model for other countries in their efforts to “de-risk” science and technology cooperation with China. China’s Ministry of Science and Technology reports that China has 115 intergovernmental science and technology agreements, some of which are being updated or renegotiated. Other countries would likely maintain science and technology agreements with China regardless of whether the U.S.-PRC STA had lapsed. But the strengthened STA language, as well as bolstered national security protections on which U.S. officials have engaged international counterparts, will be more helpful in providing well-considered guardrails for other U.S. partners to emulate or draw from than if Washington had just shut down science and technology cooperation with China.
U.S. officials will emphasize publicly—as they should—that the STA only covers government-to-government cooperation, but there is ample scope for beneficial cooperation outside of government channels. The indirect impact of the agreement and its renewal extends more broadly—both symbolically and tangibly. A U.S. life scientist not in government described the STA to one of us in an off-the-record discussion as a “normative umbrella” that benefits researchers in the United States and China more broadly.
The STA establishes clear and consistent best practices that nongovernmental actors can follow in bilateral cooperation. For example, the guidelines and commitments on data-sharing can be pointed to by U.S. and Chinese researchers alike if they are facing obstacles in the Chinese system on sharing data and results from projects outside of China.
Cancer research is one crucial area where everyone benefits. Together, China and the United States account for nearly 40 percent of the world’s 10 million annual cancer deaths. Better harmonization of clinical trials of cancer therapies could reduce global cancer-related deaths by an estimated 10 percent to 20 percent, or 1 million to 2 million lives per year, according to a Bloomberg International Cancer Coalition study.
While geopolitics may seem daunting, history offers a powerful lesson: In 1966, during the height of the Cold War, U.S. scientist  Donald Henderson and a Soviet deputy health minister joined forces to eradicate smallpox, which had killed approximately 300 million people in the 20th century alone. By 1980, the World Health Organization announced that smallpox had been eliminated worldwide.
If this kind of cooperation was possible then, there is every reason to believe that the United States and China can come together now to fight cancer. The amended STA provides renewed space for fruitful collaboration in areas that may prove to be lifesaving for both Chinese and Americans.